ASX-listed AVITA Medical rises on upbeat qtrly revenue

AVITA Medical

11/01/2022 02:21

** ASX-listed shares of AVITA Medical Inc  AVH.AX   RCEL.O 
rise as much as 5.4% to A$3.310, marking their biggest intraday
pct gain since Nov. 4, 2021
    ** The medical technology firm posts https://www.asx.com.au/asxpdf/20220111/pdf/454wsnt1g1p5dr.pdf
 total revenue of $6.9 mln for the quarter ended Dec. 31, as
compared to $5.1 mln over the same quarter in the prior period
    ** Says co will be preparing its vitiligo and soft tissue
dossiers to submit premarket supplement applications to the U.S.
Food and Drug Administration (FDA) in late 2022 for commercial
launches for those indications in 2023
    ** Stock down ~8.2% this year as of last close 
    


 (Reporting by Upasana Singh in Bengaluru)
 ((Upasana.Singh@thomsonreuters.com))